This week the Drug Enforcement Administration (DEA) has decided that marijuana will remain classified as a Schedule I substance under the Controlled Substances Act. The decision to keep marijuana in the category reserved for drugs with no accepted medical uses and a high potential for abuse was, according to the DEA, based on consultation with the Department of Health and Human Services. According to DEA administrator Chuck Rosenberg, “If the scientific understanding about marijuana changes — and it could change — then the decision could change…. But we will remain tethered to science, as we must, and as the statute demands. It certainly would be odd to rely on science when it suits us and ignore it otherwise.”
The fact that the DEA has maintained its position that marijuana has no accepted medical value may come as a surprise to many, especially given the thousands, if not millions, of seriously ill patients who currently use marijuana to treat a number of symptoms and conditions.
In a more positive development, it was also announced that the federal government will be removing major obstacles to marijuana research. The only source of federally approved research-grade marijuana has been the University of Mississippi, and it has been so difficult for researchers to obtain that it has effectively created a research monopoly held by the National Institute on Drug Abuse (NIDA). Now, universities may apply for federal approval to grown their own supply of marijuana, creating fewer roadblocks for researchers in the future.